SCHEMBL18506652

SCHEMBL18506652

CCOC(=O)C1(C(=O)OCC)C[C@H]1COCc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADAM17 P78536 2/20 0.45
LMNA P02545 4/20 0.43
KDM4E B2RXH2 4/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
POLB P06746 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
PKM P14618 1/20 0.41
MAPT P10636 1/20 0.41
ALDH1A1 P00352 1/20 0.41
OPRM1 P35372 3/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
GAA P10253 1/20 0.39
OPRD1 P41143 2/20 0.39
OPRK1 P41145 2/20 0.39
SLC22A1 O15245 1/20 0.39
SLC6A4 P31645 1/20 0.39
ADRA1A P35348 1/20 0.39
KCNH2 Q12809 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18506747 1.00 ADAM17 (0.45) ADAM17LMNAKDM4EMEN1KMT2A
SCHEMBL30707059 1.00 ADAM17 (0.45) ADAM17LMNAKDM4EMEN1KMT2A
SCHEMBL18506651 0.95 ADAM17 (0.43) ADAM17LMNAKDM4EMEN1KMT2A
SCHEMBL18506818 0.95 ADAM17 (0.43) ADAM17LMNAKDM4EMEN1KMT2A
SCHEMBL30707458 0.95 ADAM17 (0.43) ADAM17LMNAKDM4EMEN1KMT2A
SCHEMBL31460265 0.90 ADAM17 (0.41) ADAM17LMNAKDM4EMEN1KMT2A
SCHEMBL15927910 0.87 ADAM17 (0.39) ADAM17LMNAKDM4EMEN1KMT2A
SCHEMBL15337105 0.85 ADAM17 (0.44) ADAM17LMNAKDM4EMEN1KMT2A
SCHEMBL15927904 0.85 ADAM17 (0.44) ADAM17LMNAKDM4EMEN1KMT2A
SCHEMBL15927894 0.85 ADAM17 (0.44) ADAM17LMNAKDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170044156-A1 SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND MEDICINAL USE THEREOF AS HIV INTEGRASE INHIBITOR JAPAN TOBACCO INC. (JP) 2017-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170044156-A1 SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND MEDICINAL USE THEREOF AS HIV INTEGRASE INHIBITOR IMPDH1, IMPDH2, SAV1 ADAM17 2930/4885LMNA 2905/4885KDM4E 1771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.